The Association Between Prebooster Vaccination Antibody Levels and the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Abstract The correlation between anti–severe acute respiratory syndrome coronavirus 2 antibody levels and infection was reported. Here, we estimated the role of pre–fourth dose levels using data from 1098 healthcare workers. The risk of infection was reduced by 46% (95% confidence interval, 29%–59%)...

Full description

Saved in:
Bibliographic Details
Published in:Clinical infectious diseases 2023-04, Vol.76 (7), p.1315-1317
Main Authors: Barda, Noam, Canetti, Michal, Gilboa, Mayan, Asraf, Keren, Indenboim, Victoria, Weiss-Ottolenghi, Yael, Amit, Sharon, Zubli, Daniel, Doolman, Ram, Mendelson, Ella, Freedman, Laurence S, Kreiss, Yitshak, Lustig, Yaniv, Regev-Yochay, Gili
Format: Article
Language:English
Subjects:
Antibodies, Viral
COVID-19
Health Personnel
Humans
Immunization, Secondary
Vaccination
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c423t-8c7d654d10ec0296b07bc61010aa6b477f4259cdffd0e7afec478e452ce353d03
cites cdi_FETCH-LOGICAL-c423t-8c7d654d10ec0296b07bc61010aa6b477f4259cdffd0e7afec478e452ce353d03
container_end_page 1317
container_issue 7
container_start_page 1315
container_title Clinical infectious diseases
container_volume 76
creator Barda, Noam
Canetti, Michal
Gilboa, Mayan
Asraf, Keren
Indenboim, Victoria
Weiss-Ottolenghi, Yael
Amit, Sharon
Zubli, Daniel
Doolman, Ram
Mendelson, Ella
Freedman, Laurence S
Kreiss, Yitshak
Lustig, Yaniv
Regev-Yochay, Gili
description Abstract The correlation between anti–severe acute respiratory syndrome coronavirus 2 antibody levels and infection was reported. Here, we estimated the role of pre–fourth dose levels using data from 1098 healthcare workers. The risk of infection was reduced by 46% (95% confidence interval, 29%–59%) for each 10-fold increase in prebooster levels. Prebooster antibody levels could be used to optimally time boosters.
doi_str_mv 10.1093/cid/ciac886
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2735867831</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/cid/ciac886</oup_id><sourcerecordid>2735867831</sourcerecordid><originalsourceid>FETCH-LOGICAL-c423t-8c7d654d10ec0296b07bc61010aa6b477f4259cdffd0e7afec478e452ce353d03</originalsourceid><addsrcrecordid>eNp9kE1PGzEQhq2qqIS0J-7Ip6oSWrDX6489phG0SJFAhfa68tqzwpDYwfYG5R_ws-soaY8cRjN659FzeBE6peSCkpZdGmfLaKOU-IAmlDNZCd7Sj-UmXFWNYuoYnaT0RAilivBP6JgJJoSs2wl6e3gEPEspFEN2wePvkF8BPL6L0IeQMkT8Rxvj_P4989n1wW7xAjawTFh7i3NR_HLpGYcB35c4FqMZcwkhrV3UOcQtvt96G8MK8DzE4PXGxTHhGt_4AczO_BkdDXqZ4MthT9Hv66uH-c9qcfvjZj5bVKapWa6UkVbwxlIChtSt6InsjaCEEq1F30g5NDVvjR0GS0DqIm-kgobXBhhnlrAp-rb3rmN4GSHlbuWSgeVSewhj6mrJuBJSMVrQ8z1qYkgpwtCto1vpuO0o6XbVd6X67lB9oc8O4rFfgf3P_uu6AF_3QBjX75r-AgUKj5o</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2735867831</pqid></control><display><type>article</type><title>The Association Between Prebooster Vaccination Antibody Levels and the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Infection</title><source>Oxford Journals - Connect here FIRST to enable access</source><creator>Barda, Noam ; Canetti, Michal ; Gilboa, Mayan ; Asraf, Keren ; Indenboim, Victoria ; Weiss-Ottolenghi, Yael ; Amit, Sharon ; Zubli, Daniel ; Doolman, Ram ; Mendelson, Ella ; Freedman, Laurence S ; Kreiss, Yitshak ; Lustig, Yaniv ; Regev-Yochay, Gili</creator><creatorcontrib>Barda, Noam ; Canetti, Michal ; Gilboa, Mayan ; Asraf, Keren ; Indenboim, Victoria ; Weiss-Ottolenghi, Yael ; Amit, Sharon ; Zubli, Daniel ; Doolman, Ram ; Mendelson, Ella ; Freedman, Laurence S ; Kreiss, Yitshak ; Lustig, Yaniv ; Regev-Yochay, Gili</creatorcontrib><description>Abstract The correlation between anti–severe acute respiratory syndrome coronavirus 2 antibody levels and infection was reported. Here, we estimated the role of pre–fourth dose levels using data from 1098 healthcare workers. The risk of infection was reduced by 46% (95% confidence interval, 29%–59%) for each 10-fold increase in prebooster levels. Prebooster antibody levels could be used to optimally time boosters.</description><identifier>ISSN: 1058-4838</identifier><identifier>EISSN: 1537-6591</identifier><identifier>DOI: 10.1093/cid/ciac886</identifier><identifier>PMID: 36366729</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><subject>Antibodies, Viral ; COVID-19 ; Health Personnel ; Humans ; Immunization, Secondary ; Vaccination</subject><ispartof>Clinical infectious diseases, 2023-04, Vol.76 (7), p.1315-1317</ispartof><rights>The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com 2022</rights><rights>The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c423t-8c7d654d10ec0296b07bc61010aa6b477f4259cdffd0e7afec478e452ce353d03</citedby><cites>FETCH-LOGICAL-c423t-8c7d654d10ec0296b07bc61010aa6b477f4259cdffd0e7afec478e452ce353d03</cites><orcidid>0000-0001-5235-3447 ; 0000-0002-3400-235X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,786,790,1591,27957,27958</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36366729$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Barda, Noam</creatorcontrib><creatorcontrib>Canetti, Michal</creatorcontrib><creatorcontrib>Gilboa, Mayan</creatorcontrib><creatorcontrib>Asraf, Keren</creatorcontrib><creatorcontrib>Indenboim, Victoria</creatorcontrib><creatorcontrib>Weiss-Ottolenghi, Yael</creatorcontrib><creatorcontrib>Amit, Sharon</creatorcontrib><creatorcontrib>Zubli, Daniel</creatorcontrib><creatorcontrib>Doolman, Ram</creatorcontrib><creatorcontrib>Mendelson, Ella</creatorcontrib><creatorcontrib>Freedman, Laurence S</creatorcontrib><creatorcontrib>Kreiss, Yitshak</creatorcontrib><creatorcontrib>Lustig, Yaniv</creatorcontrib><creatorcontrib>Regev-Yochay, Gili</creatorcontrib><title>The Association Between Prebooster Vaccination Antibody Levels and the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Infection</title><title>Clinical infectious diseases</title><addtitle>Clin Infect Dis</addtitle><description>Abstract The correlation between anti–severe acute respiratory syndrome coronavirus 2 antibody levels and infection was reported. Here, we estimated the role of pre–fourth dose levels using data from 1098 healthcare workers. The risk of infection was reduced by 46% (95% confidence interval, 29%–59%) for each 10-fold increase in prebooster levels. Prebooster antibody levels could be used to optimally time boosters.</description><subject>Antibodies, Viral</subject><subject>COVID-19</subject><subject>Health Personnel</subject><subject>Humans</subject><subject>Immunization, Secondary</subject><subject>Vaccination</subject><issn>1058-4838</issn><issn>1537-6591</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp9kE1PGzEQhq2qqIS0J-7Ip6oSWrDX6489phG0SJFAhfa68tqzwpDYwfYG5R_ws-soaY8cRjN659FzeBE6peSCkpZdGmfLaKOU-IAmlDNZCd7Sj-UmXFWNYuoYnaT0RAilivBP6JgJJoSs2wl6e3gEPEspFEN2wePvkF8BPL6L0IeQMkT8Rxvj_P4989n1wW7xAjawTFh7i3NR_HLpGYcB35c4FqMZcwkhrV3UOcQtvt96G8MK8DzE4PXGxTHhGt_4AczO_BkdDXqZ4MthT9Hv66uH-c9qcfvjZj5bVKapWa6UkVbwxlIChtSt6InsjaCEEq1F30g5NDVvjR0GS0DqIm-kgobXBhhnlrAp-rb3rmN4GSHlbuWSgeVSewhj6mrJuBJSMVrQ8z1qYkgpwtCto1vpuO0o6XbVd6X67lB9oc8O4rFfgf3P_uu6AF_3QBjX75r-AgUKj5o</recordid><startdate>20230403</startdate><enddate>20230403</enddate><creator>Barda, Noam</creator><creator>Canetti, Michal</creator><creator>Gilboa, Mayan</creator><creator>Asraf, Keren</creator><creator>Indenboim, Victoria</creator><creator>Weiss-Ottolenghi, Yael</creator><creator>Amit, Sharon</creator><creator>Zubli, Daniel</creator><creator>Doolman, Ram</creator><creator>Mendelson, Ella</creator><creator>Freedman, Laurence S</creator><creator>Kreiss, Yitshak</creator><creator>Lustig, Yaniv</creator><creator>Regev-Yochay, Gili</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-5235-3447</orcidid><orcidid>https://orcid.org/0000-0002-3400-235X</orcidid></search><sort><creationdate>20230403</creationdate><title>The Association Between Prebooster Vaccination Antibody Levels and the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Infection</title><author>Barda, Noam ; Canetti, Michal ; Gilboa, Mayan ; Asraf, Keren ; Indenboim, Victoria ; Weiss-Ottolenghi, Yael ; Amit, Sharon ; Zubli, Daniel ; Doolman, Ram ; Mendelson, Ella ; Freedman, Laurence S ; Kreiss, Yitshak ; Lustig, Yaniv ; Regev-Yochay, Gili</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c423t-8c7d654d10ec0296b07bc61010aa6b477f4259cdffd0e7afec478e452ce353d03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Antibodies, Viral</topic><topic>COVID-19</topic><topic>Health Personnel</topic><topic>Humans</topic><topic>Immunization, Secondary</topic><topic>Vaccination</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Barda, Noam</creatorcontrib><creatorcontrib>Canetti, Michal</creatorcontrib><creatorcontrib>Gilboa, Mayan</creatorcontrib><creatorcontrib>Asraf, Keren</creatorcontrib><creatorcontrib>Indenboim, Victoria</creatorcontrib><creatorcontrib>Weiss-Ottolenghi, Yael</creatorcontrib><creatorcontrib>Amit, Sharon</creatorcontrib><creatorcontrib>Zubli, Daniel</creatorcontrib><creatorcontrib>Doolman, Ram</creatorcontrib><creatorcontrib>Mendelson, Ella</creatorcontrib><creatorcontrib>Freedman, Laurence S</creatorcontrib><creatorcontrib>Kreiss, Yitshak</creatorcontrib><creatorcontrib>Lustig, Yaniv</creatorcontrib><creatorcontrib>Regev-Yochay, Gili</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Barda, Noam</au><au>Canetti, Michal</au><au>Gilboa, Mayan</au><au>Asraf, Keren</au><au>Indenboim, Victoria</au><au>Weiss-Ottolenghi, Yael</au><au>Amit, Sharon</au><au>Zubli, Daniel</au><au>Doolman, Ram</au><au>Mendelson, Ella</au><au>Freedman, Laurence S</au><au>Kreiss, Yitshak</au><au>Lustig, Yaniv</au><au>Regev-Yochay, Gili</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Association Between Prebooster Vaccination Antibody Levels and the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Infection</atitle><jtitle>Clinical infectious diseases</jtitle><addtitle>Clin Infect Dis</addtitle><date>2023-04-03</date><risdate>2023</risdate><volume>76</volume><issue>7</issue><spage>1315</spage><epage>1317</epage><pages>1315-1317</pages><issn>1058-4838</issn><eissn>1537-6591</eissn><notes>ObjectType-Article-1</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-2</notes><notes>content type line 23</notes><abstract>Abstract The correlation between anti–severe acute respiratory syndrome coronavirus 2 antibody levels and infection was reported. Here, we estimated the role of pre–fourth dose levels using data from 1098 healthcare workers. The risk of infection was reduced by 46% (95% confidence interval, 29%–59%) for each 10-fold increase in prebooster levels. Prebooster antibody levels could be used to optimally time boosters.</abstract><cop>US</cop><pub>Oxford University Press</pub><pmid>36366729</pmid><doi>10.1093/cid/ciac886</doi><tpages>3</tpages><orcidid>https://orcid.org/0000-0001-5235-3447</orcidid><orcidid>https://orcid.org/0000-0002-3400-235X</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1058-4838
ispartof Clinical infectious diseases, 2023-04, Vol.76 (7), p.1315-1317
issn 1058-4838
1537-6591
language eng
recordid cdi_proquest_miscellaneous_2735867831
source Oxford Journals - Connect here FIRST to enable access
subjects Antibodies, Viral
COVID-19
Health Personnel
Humans
Immunization, Secondary
Vaccination
title The Association Between Prebooster Vaccination Antibody Levels and the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Infection
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-22T05%3A33%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Association%20Between%20Prebooster%20Vaccination%20Antibody%20Levels%20and%20the%20Risk%20of%20Severe%20Acute%20Respiratory%20Syndrome%20Coronavirus%202%20Infection&rft.jtitle=Clinical%20infectious%20diseases&rft.au=Barda,%20Noam&rft.date=2023-04-03&rft.volume=76&rft.issue=7&rft.spage=1315&rft.epage=1317&rft.pages=1315-1317&rft.issn=1058-4838&rft.eissn=1537-6591&rft_id=info:doi/10.1093/cid/ciac886&rft_dat=%3Cproquest_cross%3E2735867831%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c423t-8c7d654d10ec0296b07bc61010aa6b477f4259cdffd0e7afec478e452ce353d03%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2735867831&rft_id=info:pmid/36366729&rft_oup_id=10.1093/cid/ciac886&rfr_iscdi=true